Wellness Programs
Spirometry
Sort By:
Vitalograph copd-6 Range
For the early detection of COPD – quickly, simply & accurately

  • Fast screening of at-risk groups
  • Provides quick assessment of need for full spirometry
  • Displays FEV1, FEV6, FEV1/FEV6 measured and percent of predicted
  • Obstructive Index and COPD classification indicator
  • Indication of effective Lung Age
  • NHANES III predicted value sets
  • Small, light weight, portable unit
  • Designed for multi-patient use with SafeTway® mouthpieces
  • Full size color report from USB version
  • Large, easy to read display

The new Vitalograph copd-6 offers fast, simple and effective screening of those at risk for COPD. The dual zone indicators provide an instant indication of both the obstructive index and the COPD classification.
Using NHANESIII predicted values, the copd-6 measures and displays FEV1, FEV6, FEV1/FEV6 and percent of predicted. The copd-6 USB links to your PC to produce electronic pdf for attaching to patient’s file and hard copy color reports.
Those with measurements within the normal range can be screened out, allowing diagnostic spirometry resources to be focused on those most at risk.

Vitalograph copd-6 usb
For COPD screening compatible with Vitalograph Reports Software

The copd-6 usb identifies those at risk of COPD at the pre-symptomatic stage to allow early medical intervention and facilitate better clinical outcomes.
This pioneering device screens out those whose FEV1 is normal, and who therefore do not have COPD,without the risk of false COPD negatives.
By linking to your PC the copd-6 usb produces electronic & hard copy reports.

  • Predicted values, 3 test results, best test, % predicted and lung age automatically tabulated
  • Obstructive index, COPD (GOLD) Classification indicator
  • BMI calculated
  • Blow quality indicator
  • Interpretation of results
  • Interpretation of results

Reports include:
  • Single page record for screening or monitoring
  • Various report options
  • Optional subject ID and name fields (weight field optional)
  • Ability to add comments to the report
  • Age, height, gender, device ID, time/date fields automatically populated
  • Can automatically name the PDF file
  • Ability to add comments to the report


COPD SAMPLE REPORT

4000 SERIES COMPAIRISON CHART


COPD Medical Facts:
About one in four adults age 35 and over can be expected to develop chronic obstructive pulmonary disease (COPD), new research suggests.

The average woman in her mid-30s is more than three times as likely to develop the progressive and potentially deadly lung disorder as breast cancer during her lifetime, says respiratory disease specialist Andrea Gershon, MD. She says the average man is more than three times as likely to develop COPD as prostate cancer.
"This is a disease that is underreported. But it is still the fourth leading cause of death worldwide and it is projected to be the third cause of death within two decades," Gershon tells WebMD.

Symptoms of COPD include:

  • Constant coughing, sometimes called “smoker’s cough”
  • Shortness of breath while doing activities you used to be able to do
  • Excess sputum production
  • Feeling like you can’t breathe
  • Not being able to take a deep breath
  • Wheezing

Genetic Factors
In some people, COPD is caused by a genetic condition known as alpha-1 antitrypsin, or AAT, deficiency. While very few people know they have AAT deficiency, it is estimated that as many as 100,000 Americans have it. People with AAT deficiency can get COPD even if they have never smoked or had long-term exposure to harmful pollutants.

Mild COPD: The first stage of COPD is termed “Mild COPD”. Typically, your spirometry test indicates mild airflow restriction. During the first stage of COPD, it is difficult to breath after simple activities.It is much better to begin COPD treatment during the early COPD stages. Especialy when you may not even be aware of decreased lung ability. Since there is no cure for this condition, getting treatment early will ease the discomfort and quite likely hold it’s progression to a slower rate.

Moderate COPD: The second stage of COPD is termed “Moderate COPD”. Typically, your spirometry test indicates a worsening airflow restriction.
Its at this stage when people usually seek medical attention. Due to breathing issues, many will cut down on certain day to day activities. As with the mild stage, treatments are available, but no cure. There’s a chance that once at this stage, the disease will continue to progress, leaving one to battle severe COPD.

The third stage of COPD is termed “Severe COPD”. Typically, your spirometry test indicates severe air flow restriction.
This stage of the disease can be unbearable for some. It is at this stage when one realizes just how afflicting this disease is. Treatment helps to alleviate some symptoms. treatment can ease discomfort and make life more managable. Especially if treatments are applied during the early COPD stages. it is a progressive disease, but as it’s always to one’s advantage to catch it early.

The stages of COPD are often defined according to your symptoms plus a measure of how well your lungs work, called your "lung function."

Mild COPD (stage 1)
Usually, but not always, a chronic cough that often brings up mucus from the lungs
Lung function FEV1 of 80% of normal or higher

Moderate COPD (stage 2)
Chronic cough with a lot of mucus
Shortness of breath, especially with exercise
An occasional COPD flare-up
Lung function FEV1 of 50% to 79%

Severe COPD (stage 3)
Chronic cough with a lot of mucus
Shortness of breath
Fatigue and a reduced ability to exercise
Repeated and sometimes severe COPD flare-ups
Lung function FEV1 of 30% to 49%

Very severe COPD (stage 4)
Chronic cough with a lot of mucus
Severe shortness of breath
Weight loss
Blue skin color, especially in the lips, fingers, and toes (called cyanosis)
Fluid buildup in the legs and feet (called edema)
Life-threatening COPD flare-ups
Lung function FEV1 of less than 30%, or of less than 50% along with chronic respiratory failure (a condition caused by carbon dioxide that stays in the lungs)


The importance of testing for COPD


  • COPD is the third leading cause of death in the United States.
  • The National Heart, Lung and Blood Institute estimates that 12 million adults have COPD and another 12 million adults have COPD and another 12 million are undiagnosed or developing COPD.
  • COPD kills more women that men each year. In 2006, COPD killed more American women than breast cancer and diabetes combined.

With an emphasis on preventive care, catching, diagnosing and treating disease states early is critical to improved outcomes. This is especially the case with chronic obstructive pulmonary disease (COPD), a progressive disease that makes it hard to breathe, according to the National Heart, Lung and Blood Institute. COPD can cause coughing that produces large amounts of mucus, wheezing, shortness of breath, chest tightness, and other symptoms. COPD is slow developing, but has very serious health implications.

Long-term exposure to lung irritants that damage the lungs, and the airways usually is the cause of COPD. In the United States, the most common irritant that causes COPD is cigarette smoke. Pipe,cigar, and other types of tobacco smoke also can cause COPD, especially if the smoke is inhaled. Breathing in secondhand smoke, air pollution, or chemical fumes or dust from the environment or workplace also can contribute to COPD. 

Vitalograph Mini Safetway Mouthpieces Pediatric (50ct)  [ VIT012-20980-A ]
Price: $46.99
Quantity:
  
Vitalograph Safetway Adult Mounthpieces (200ct)  [ VIT010-20242-A ]
Price: $72.00
Quantity:
  
Vitalograph Safetway Noseclips (200ct)  [ VIT015-20303-A ]
Price: $79.00
Quantity:
  
Vitalograph COPD-6 USB  [ VIT002-40451 ]
Price: $199.00
Quantity:
  

Vitalograph copd-6 Range
For the early detection of COPD – quickly, simply & accurately

  • Fast screening of at-risk groups
  • Provides quick assessment of need for full spirometry
  • Displays FEV1, FEV6, FEV1/FEV6 measured and percent of predicted
  • Obstructive Index and COPD classification indicator
  • Indication of effective Lung Age
  • NHANES III predicted value sets
  • Small, lightweight, portable unit
  • Designed for multi-patient use with SafeTway® mouthpieces
  • Full size color report from USB version
  • Large, easy to read display


The new Vitalograph copd-6 offers fast, simple and effective screening of those at risk for COPD. The dual zone indicators provide an instant indication of both the obstructive index and the COPD classification.

Using NHANESIII predicted values, the copd-6 measures and displays FEV1, FEV6, FEV1/FEV6 and percent of predicted. The copd-6 USB links to your PC to produce an electronic PDF for attaching to patient’s file and hard copy color reports.

Patients with measurements within the normal range can be screened out, allowing diagnostic spirometry resources to be focused on those most at risk.


Vitalograph copd-6
For simple, fast & accurate COPD screening

The copd-6 identifies those at risk of COPD at the pre-symptomatic stage to allow early medical intervention and facilitate better clinical outcomes.
This pioneering device screens out those with normal FEV1, and who therefore do not have COPD, without the risk of false COPD negatives, allowing spirometry resources to be focused on those most at risk.

  • Detects early COPD - quickly, simply and accurately
  • Identifies those at risk of COPD at the pre-symptomatic stage to allow early medical intervention and facilitate better clinical outcomes
  • Screens out those with normal FEV1, and who therefore do not have COPD, without the risk of false COPD negatives
  • Facilitates 'case selection' so that spirometry resources can be focused on those most likely to be diagnosed with COPD
  • Monitors COPD patients using their 'number', the obstructive index, FEV1 as a percent of predicted
  • Displays FEV1, FEV6, ratio and percent of predicted, obstructive index, COPD classification and lung age
  • Built-in quality of blow indicator on a large, easy-to-read display
  • Easy to clean flowhead
  • Can be used with hygienic SafeTway mouthpieces or a BVF
  • Displays the GOLD COPD classification (stage I - IV) to help recognize the need for a change in the patient's management plan
  • Requires only minimal instruction for use by non-respiratory specialists



4000 SERIES COMPAIRISON CHART


COPD Medical Facts:
About one in four adults age 35 and over can be expected to develop chronic obstructive pulmonary disease (COPD), new research suggests.

The average woman in her mid-30s is more than three times as likely to develop the progressive and potentially deadly lung disorder as breast cancer during her lifetime, says respiratory disease specialist Andrea Gershon, M.D. According to Gershon, the average man is more than three times as likely to develop COPD as prostate cancer:
"This is a disease that is underreported. But it is still the fourth leading cause of death worldwide and it is projected to be the third cause of death within two decades," Gershon tells WebMD.

Symptoms of COPD include:

  • Constant coughing, sometimes called “smoker’s cough”
  • Shortness of breath while doing activities you used to be able to do
  • Excess sputum production
  • Feeling like you can’t breathe
  • Not being able to take a deep breath
  • Wheezing


Genetic Factors
In some people, COPD is caused by a genetic condition known as alpha-1 antitrypsin, or AAT, deficiency. While very few people know they have AAT deficiency, it is estimated that as many as 100,000 Americans have it. People with AAT deficiency can get COPD even if they have never smoked or had long-term exposure to harmful pollutants.

Mild COPD: The first stage of COPD is termed “Mild COPD”. Typically, your spirometry test indicates mild airflow restriction. During the first stage of COPD, it is difficult to breathe after simple activities. It is much better to begin COPD treatment during the early COPD stages. This is especially true considering you may not even be aware of decreased lung ability. Since there is no cure for this condition, getting treatment early will ease the discomfort and quite likely hold its progression to a slower rate.

Moderate COPD: The second stage of COPD is termed “Moderate COPD”. Typically, your spirometry test indicates a worsening airflow restriction.
It’s at this stage when people usually seek medical attention. Due to breathing issues, many will cut down on certain day-to-day activities. As with the mild stage, treatments exist, but no cure is available. There’s a chance that once at this stage, the disease will continue to progress, leaving one to battle severe COPD.

Severe COPD: Typically, your spirometry test indicates severe air flow restriction.
This stage of the disease can be unbearable for some. It is at this stage that one realizes just how afflicting this disease is. Treatment helps to alleviate some symptoms. Treatment can ease discomfort and make life more manageable. This is especially true if treatments are applied during the early COPD stages. COPD is a progressive disease, but as it’s always advantageous to catch it early.

The stages of COPD are often defined according to your symptoms plus a measure of how well your lungs work, which is called your "lung function."

Mild COPD (stage 1)
Usually, but not always, a chronic cough that brings mucus up from the lungs
Lung function FEV1 of 80% of normal or higher

Moderate COPD (stage 2)
Chronic cough with a lot of mucus
Shortness of breath, especially with exercise
An occasional COPD flare-up
Lung function FEV1 of 50% to 79%

Severe COPD (stage 3)
Chronic cough with a lot of mucus
Shortness of breath
Fatigue and a reduced ability to exercise
Repeated and sometimes severe COPD flare-ups
Lung function FEV1 of 30% to 49%

Very severe COPD (stage 4)
Chronic cough with a lot of mucus
Severe shortness of breath
Weight loss
Blue skin color, especially in the lips, fingers, and toes (called cyanosis)
Fluid buildup in the legs and feet (called edema)
Life-threatening COPD flare-ups
Lung function FEV1 of less than 30%, or of less than 50% along with chronic respiratory failure (a condition caused by carbon dioxide that stays in the lungs)

The importance of testing for COPD

  • COPD is the third leading cause of death in the United States.
  • The National Heart, Lung and Blood Institute estimates that 12 million adults have COPD and another 12 million are undiagnosed or developing COPD.
  • COPD kills more women than men each year. In 2006, COPD killed more American women than breast cancer and diabetes combined.


An emphasis on preventive care, catching, diagnosing and treating disease states early is critical to improved outcomes. This is especially the case with chronic obstructive pulmonary disease (COPD), a progressive disease that makes it hard to breathe, according to the National Heart, Lung and Blood Institute. COPD can cause coughing that produces large amounts of mucus, wheezing, shortness of breath, chest tightness, and other symptoms. COPD is slow developing, but has very serious health implications.

Long-term exposure to irritants that damage the lungs and airways is typically the cause of COPD. In the United States, the most common irritant that causes COPD is cigarette smoke. Pipe, cigar, and other types of tobacco smoke also can cause COPD, especially if the smoke is inhaled. Breathing in secondhand smoke, air pollution, or chemical fumes or dust from the environment or workplace also can contribute to COPD. 

Vitalograph Mini Safetway Mouthpieces Pediatric (50ct)  [ VIT012-20980 ]
Price: $46.99
Quantity:
  
Vitalograph Safetway Adult Mounthpieces (200ct)  [ VIT010-20242 ]
Price: $72.00
Quantity:
  
Vitalograph Safetway Noseclips (200ct)  [ VIT015-20303 ]
Price: $79.00
Quantity:
  
Vitalograph COPD-6  [ VIT001-40201 ]
Price: $129.00
Quantity:
  
NEW VITALOGRAPH micro
The Ultimate Low Cost, High Performance Spirometer

The Vitalograph® micro is a high quality hand-held spirometer at a great value price from the leading provider of spirometry devices to general healthcare and occupational health markets. This reliable, easy-to-use, entry-level model offers all required functionalities in a full feature spirometer. The micro is unrivalled in its price range and is the ideal choice for fast, accurate testing in environments where mobility is important.
The micro features the same high performance measuring technology used across the Vitalograph range and requires no user calibration. In contrast to turbine spirometers the micro does not feature any sensitive moving parts, guaranteeing robustness and the highest possible measuring accuracy - even at very low or high rates.




  • Low cost, entry-level model from the leader in general healthcare and occupational health spirometry test devices 

  • Durable measurement technology 

  • No need for expensive disposable sensors, turbines, spirettes or ow tubes 

  • No user calibration required 

  • Optimal hygiene via Vitalograph Bacterial Viral Filters (BVFTM) 

  • Touchscreen for simple and intuitive operation 

  • Includes Vitalograph Reports Software for creating editable PDF reports 
(for printing, ling and uploading to electronic medical record (EMR) systems) 

  • Features latest GLI spirometry predicted equations and Z-scores 


Links:
Vitalograph_BVF_FAQ

Vitalografh 2820 BVF Bacterial/viral Filters (50ct)  [ VIT110-28350 ]
Price: $49.99
Quantity:
  
Vitalograph micro Spirometer (1ea)  [ VIT100-63301 ]
Price: $852.00
Quantity:
  

The Latest Innovation from SDI Touch Screen Spirometry


The Astra300™ puts the sophistication and simplicity of a touch screen in the palm of your hand. Enter data, test patients, and send and print reports with precision and ease. Easily report your choice of up to 40 spirometry test parameters, all measured accurately and precisely.




Astra300™ Features

Astra300™ Puts Sophisticated Simplicity in the Palm of Your Hand.

The Touchscreen Makes It Easy. SDI Makes It Accurate.
Easily report your choice of up to 40 spirometry test parameters, all measured accurately and precisely with the highly sophisticated Astra300 Spirometer. Using the bright and sensitive touchscreen, you can easily access multifunctional capabilities and view both graphic and tabular data. Entering patient data, patient testing and reporting couldn't be easier. Exporting test data to a printer or PC via USB is quickly accomplished with just a few stylus taps on the touchscreen. A Bluetooth-to-PC module is available as as option for truly wireless communication.



AccuFlo™ Digital Turbine


The AccuFlo™ bidirectional turbine with optoelectronic rotary sensor is easily detached for cleaning. Sapphire bearings ensure optimal performance for the life of the turbine. AccuFlo has a unique flow trigger algorithm that allows tidal breathing prior to the patient expiratory effort making the spirometry test easier for the patient and insuring quality test results.



The Touchscreen Makes It Easy.
SDI Makes It Accurate.


  • Bright, sensitive touchscreen
  • Multifunctional capabilities
  • View both graphic and tabular data
  • Easy to use
  • Export test data to a printer or PC via USB
  • NIOSH and SSA Guidelines Compliant
  • Optional Bluetooth-to-PC



Choose whatever testing configuration fits your needs best
:

Test patients in your office or lab, with a wide array of testing configurations.
Observe test results in real time.
Download test results to the patient's permanent record.
Perform interactive real-time testing on your PC.
Save results to permanent records or print hard copies of selected data.



AstraGuard™ Filters

Starter pack of 10 AstraGuard™ PFT filters, designed expressly for the Astra series, included with every purchase.



Links:
Astra300brochure.pdf
Astraguard Filter (50ct)  [ SDI020-29-7990-050 ]
Price: $87.39
Quantity:
  
Astraguard Filter (100ct)  [ SDI021-29-7990-100 ]
Price: $167.79
Quantity:
  
Astraguard Filter (200ct)  [ SDI022-29-7990-200 ]
Price: $349.49
Quantity:
  
Astra 300 Calibration Syringe (Ea)  [ SDI010-29-5034 ]
Price: $414.49
Quantity:
  
Astraguard Filter (300ct)  [ SDI023-29-7990-300 ]
Price: $492.79
Quantity:
  
Astra 300 Spirometer  [ SDI001-29-5300 ]
Reg Pric: $1,161.99
SALE Price: $890.00
Offer Ends October 31, 2018
Quantity:
  
Sort By: